格隆汇2月6日丨赛托生物(300583.SZ)公布，公司控股子公司山东斯瑞药业有限公司（简称"斯瑞药业"） 已通过高新技术企业审查并于近日取得由山东省科学技术厅、山东省工业和信息化厅、山东省财政厅、 国家税务总局山东省税务局联合颁发的高新技术企业证书原件，发证时间：2025年12月8日，证书编号 为：GR202537002998，有效期三年。 ...

格隆汇2月6日丨贵研铂业(600459.SH)在投资者互动平台表示，公司有具备完全自主知识产权的铂类抗 癌创新药正处于临床前研究中。随着老龄化社会的加剧，铂类抗癌药市场前景看好，对此公司制定有详 细的未来发展规划，但由于受原料药监管政策以及市场竞争等多种因素的影响，未来发展具有一定的不 确定性。 ...

Core Viewpoint - The company, Lifesun Pharmaceutical, has received approval from the National Medical Products Administration for the listing application of adenine phosphate raw material, which is expected to enhance its market competitiveness and create synergy with its formulation products [1] Group 1: Company Announcement - Lifesun Pharmaceutical announced the receipt of the approval notice for the listing application of adenine phosphate raw material from the National Medical Products Administration [1] - Adenine phosphate is a component of nucleic acids and coenzymes, involved in the synthesis of DNA and RNA in the body, and is clinically used to prevent and treat leukopenia caused by various reasons [1] Group 2: Market Implications - The approval of adenine phosphate raw material is expected to facilitate industrial synergy with the company's formulation products, thereby enhancing market competitiveness [1]

Investment Rating - The report assigns a "Buy" rating for the company, indicating an expected stock price increase of over 15% within the next six months [4]. Core Insights - The company has signed a strategic research and development collaboration agreement with AstraZeneca, granting AstraZeneca exclusive global rights (excluding Greater China) to the company's weight management product portfolio, including a clinical-ready project SYH2082 and three preclinical projects. The company will receive an upfront payment of $1.2 billion, with potential milestone payments of up to $3.5 billion for research and $13.8 billion for sales, along with a double-digit percentage royalty on net sales [1][2]. - The collaboration marks an upgrade from single product licensing to platform licensing, reflecting AstraZeneca's strong recognition of the company's long-acting peptide and AI pharmaceutical technology platforms [1]. - The company is advancing its proprietary sustained-release drug delivery technology and AI drug discovery platform, which enhances patient compliance by allowing for monthly or longer dosing intervals [2]. Financial Summary - The company's projected revenues for 2025-2027 are estimated at 28.8 billion, 35.9 billion, and 32.5 billion CNY, respectively, with a compound annual growth rate (CAGR) of 24.62% in 2026 [3]. - The net profit attributable to the parent company is forecasted to be 5.34 billion, 7.87 billion, and 6.76 billion CNY for 2025-2027, with corresponding earnings per share (EPS) of 0.46, 0.68, and 0.59 CNY [3]. - The current market capitalization is approximately 112.23 billion HKD, with a total share count of 11,522 million [4].

2月6日，新诺威盘中上涨2.05%，截至10:08，报35.38元/股，成交1.05亿元，换手率0.22%，总市值 496.94亿元。 截至1月30日，新诺威股东户数1.75万，较上期增加0.28%；人均流通股80349股，较上期减少0.27%。 2025年1月-9月，新诺威实现营业收入15.93亿元，同比增长7.71%；归母净利润-2404.89万元，同比减少 117.26%。 分红方面，新诺威A股上市后累计派现6.51亿元。近三年，累计派现5.00亿元。 机构持仓方面，截止2025年9月30日，新诺威十大流通股东中，香港中央结算有限公司位居第二大流通 股东，持股1778.22万股，相比上期减少321.69万股。中欧医疗健康混合A（003095）位居第三大流通股 东，持股1632.25万股，相比上期减少386.14万股。工银前沿医疗股票A（001717）位居第四大流通股 东，持股1400.01万股，相比上期增加200.01万股。汇添富创新医药混合A（006113）位居第五大流通股 东，持股1227.70万股，相比上期增加248.44万股。易方达创业板ETF（159915）位居第九大流通股东， 持股786.8 ...

证券代码：600062 证券简称：华润双鹤 公告编号：临2026－009 华润双鹤药业股份有限公司 第十届董事会第十七次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 同意公司为满足"十五五"战略发展需要，精准匹配患者临床需求，强化营销体系建设，推进营销资源整 合，组建营销管理中心。 11票同意，0票反对，0票弃权。 特此公告。 华润双鹤药业股份有限公司 公司第十届董事会第十七次会议的召开符合《公司法》和公司《章程》的有关规定。本次会议通知和材 料于2026年2月2日以邮件方式向全体董事发出，会议于2026年2月5日以通讯方式召开。出席会议的董事 应到11名，亲自出席会议的董事11名。 二、董事会会议审议情况 1、关于2026年境外佣金预算的议案 11票同意，0票反对，0票弃权。 2、关于组建营销管理中心的议案 一、董事会会议召开情况 董 事 会 2026年2月6日 ...

证券日报网讯 2月5日，德源药业发布2025年年度业绩快报公告称，公司2025年实现营业收入1，057， 759，831.41元，同比增长21.80%；归属于上市公司股东的净利润为236，929，075.58元，同比增长 33.87%。 （文章来源：证券日报） ...

Core Viewpoint - The company announced an adjustment to the repurchase price of restricted stock and the cancellation of certain stock options due to changes in eligibility and performance criteria [1] Group 1: Stock Repurchase and Adjustment - The company plans to adjust the repurchase price of reserved restricted stock from 8.56 yuan per share to 8.35 yuan per share [1] - This adjustment follows the completion of the company's 2024 annual equity distribution [1] Group 2: Cancellation of Stock Options - The company intends to cancel a total of 87,000 shares of restricted stock held by seven individuals who no longer qualify for stock incentives and two individuals who did not meet personal performance assessment requirements [1] - This cancellation is in accordance with the company's 2021 restricted stock incentive plan and the authorization from the second extraordinary general meeting of shareholders in 2021 [1]

Core Viewpoint - The company has experienced rapid growth in its CDMO projects, which are now entering the commercialization phase, contributing to an increase in CDMO capacity utilization [2] Group 1: CDMO Project Growth - The number of CDMO projects has been steadily increasing in recent years [2] - The transition to commercial production is expected to enhance capacity utilization for CDMO [2] Group 2: Business Performance Insights - The CDMO projects and capacity involve multiple subsidiaries and numerous production lines, indicating that strong performance in some production lines does not fully represent the overall business situation [2] - The company advises investors to rely on disclosed announcements for accurate business performance assessments and to exercise caution in their analyses [2]

Group 1 - The company, Aoke Co., Ltd., is currently in the process of applying for the approval of its self-developed active pharmaceutical ingredient, polyethylene glycol 3350, which is intended for use in medications for treating constipation or preoperative bowel cleansing [2] - The polyethylene glycol 3350 products, including the compound polyethylene glycol (3350) electrolyte powder, are specifically designed for the treatment of constipation [2] - The active pharmaceutical ingredient is still in the review and approval stage and has not yet been launched for sale [2]